Ng, J and Ganesan, V (2011) Expert opinion on emerging drugs in childhood arterial ischemic stroke. EXPERT OPIN EMERG DR , 16 (2) 363 - 372. 10.1517/14728214.2011.565050.
Full text not available from this repository.
Areas covered: This review article summarizes the current pharmacological treatments of childhood AIS, the evidence supporting these and proposes future treatment targets directed at underlying disease mechanisms. This is categorized into acute management, secondary prevention, emerging treatments and future treatments.Expert opinion: There is a paucity of robust data supporting current treatment approaches in childhood AIS. There are currently no recommended acute treatments; the role of thrombolysis in children remains to be determined. Aspirin, heparin and warfarin are used as secondary prevention therapies, but have not been shown to be superior to placebo. Non-atheromatous arteriopathy is now recognized as an important risk factor for recurrent AIS in children; further understanding of its etiology and pathophysiology could lead to identification of future therapeutic targets.
|Title:||Expert opinion on emerging drugs in childhood arterial ischemic stroke|
|Keywords:||arterial ischemic stroke, childhood, thrombolysis, TISSUE-PLASMINOGEN ACTIVATOR, NERVOUS-SYSTEM VASCULITIS, SICKLE-CELL-DISEASE, PEDIATRIC STROKE, FOLLOW-UP, CEREBRAL ARTERIOPATHIES, RISK-FACTORS, CHILDREN, THROMBOLYSIS, PREVENTION|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Child Health > Department of Neurosciences and Mental Health > ICH - Neurosciences Unit|
Archive Staff Only: edit this record